{
  "docId": "019de072-e9f7-73aa-b63d-f50108da815f",
  "docSlug": "8dc30a1d33d144ab07b1459d0ae0e445",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 43 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 43,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "before_after",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide contrasts clinical efficacy data (waterfall plot) with a clinical trial design schematic.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-e9f7-73aa-b63d-f50108da815f/28",
  "deckHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f",
  "deckJsonHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f.json",
  "deckAnchorHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.03,
        "y": 0.8
      },
      "kind": "callout",
      "text": "HER2-low/HER2-null tumour cells could have around five times more TROP2 receptors per cell versus HER2",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "300077a1-dd69-4e9f-bcee-5907ff70890f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.03,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Waterfall plot of best change from baseline in target lesion size",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fd78212-356b-48a0-b84b-c24f11abaa83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.55,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "TROPION-Breast02 study design flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b30430c-4bf5-4332-8b6c-9305da9da5df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Schmid ESMO Breast 2022, Abstract #166MO. Dato-DXd = datopotamab deruxtecan; HER2-negative = human epidermal growth factor receptor 2 negative; HR- = hormone-receptor negative; PD-L1 = programmed death-ligand 1; ORR = objective response rate; CI = confidence interval; TROP2 = trophoblast antigen 2; TNBC = triple negative breast cancer; mBC = metastatic breast cancer; PD-1 = programmed cell death protein 1; ECOG = Eastern Cooperative Oncology Group; PS = performance status; PFS = progression-free survival; OS = overall survival; DoR = duration of response.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dac156b4-aee2-4f67-ba17-8a2d216bf5ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Dato-DXd could address “triple negative” patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b15bba04-43f8-4d96-a9cd-91078c222604",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "TROPION-Breast02 Phase III in HER2-negative/HR-negative breast cancer",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a16b56c-cde7-4fda-b4bb-1634e1ea56ff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before/after framing",
      "slug": "before-after-framing",
      "agent": null,
      "layer": "slide",
      "matchId": "6c64e794-f99d-4c5c-bd61-d5a830a0a571",
      "evidence": "type: before_after",
      "confidence": 0.7
    },
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "e84034c6-143e-441f-909c-7fd100d4058f",
      "evidence": "chart/waterfall: Waterfall plot of best change from baseline in target lesion size",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}